Top

Taking a novel approach to drug development

Clinical Trials

Lantern Pharma is recruiting for two Phase 2 clinical trials:
1) LP-100 for AR-targeted and Docetaxel-Pretreated mCRPC Patients 2) LP-300 for Never-Smokers with NSCLC Adenocarcinoma

See more information below.

Lantern Pharma Oncology Pipeline

Drug Name
Indication
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-100

mCRPC
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-300

NSCLC
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-184

GBM
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Pediatric ATRT
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Pancreatic
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Bladder
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Prostate
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-284

Hematologic & Solid Tumors
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-A18 (ADC Programs)

Solid Tumor
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration
Drug Name
Indication
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-100

mCRPC
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-300

NSCLC
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Pancreatic
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-184

CNS Cancers - Glioblastoma
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-184

CNS Cancers - ATRT
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Bladder
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-184

Prostate
Discovery
Preclinical
IND/CTA Filed
Phase I
Phase II
Phase III
Pre-Registration

LP-284

Hematologic Cancers
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-A18

ADC - Solid Tumors
Discovery
Preclinical
IND Enabling
Phase I
Phase II
Phase III
Pre-Registration

LP-100 for AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

STAGE

Phase 2

DISEASE

Metastatic Castration-Resistant Prostate Cancer

TREATMENT

Irofulven + Prednisolone 10mg

LOCATION OF TRIAL

Rigshospitalet, Dept. of Oncology
Copenhagen, Denmark, 2100

This study seeks to evaluate the anti-tumor effect after treatment of Irofulven (LP-100) in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients. A drug response predictor (DRP®) biomarker in prostate cancer patients will identify patients likely to respond to and benefit from treatment with Irofulven.

For more information on the ongoing Phase 2 study of Irofulven in patients with mCRPC, please visit the
study page.

LP-300 for Never-smokers with NSCLC Adenocarcinoma 

STAGE

Phase 2

DISEASE

Non-Small Cell Lung Cancer

TREATMENT

LP-300 + Carboplatin and Pemetrexed

LOCATION OF TRIAL

TBD

The purpose of the LP-300 clinical trial is to evaluate LP-300 in combination with Carboplatin and Pemetrexed in Never-Smoker Patients with Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors.

The ClinicalTrials.gov page with more information on the Phase 2 study of LP-300 in patients with NSCLC is forthcoming.